Insulin‐producing pancreatic β cells are functionally impaired or destroyed in diabetes mellitus. The onset of type 1 diabetes (T1D) represents the culmination of a prolonged prediabetic phase of immune‐mediated β‐cell destruction. To assess the in vivo metabolic status of these cells, we used the ATP‐sensitive firefly luciferase bioluminescence imaging approach, as a noninvasive probe to monitor pathological alterations in β‐cell function in the nonobese‐diabetic (NOD) mouse model of T1D. Hence, we generated the Tolβ‐NOD transgenic mice in which doxycycline‐induc‐ible luciferase gene is selectively expressed in β cells. A sharp reduction in bioluminescence emitted in vivo from β cells at the early stages, preceded by several weeks of a limited reduction in β‐cell mass. Since this decline could be due to the ongoing inflammatory process occurring in vivo , we exposed control islets to inflammatory cytokines and observed a dramatic decrease in luciferase luminescence, which appears to be due in part to a decrease in protein levels and a drop in intracellular ATP levels. This is the first evidence that selective expression of the luciferase gene represents a sensitive method for noninvasive in vivo monitoring of early β‐cell dysfunction, subtle metabolic changes, such as endogenous ATP levels, indicative of a pathological condition in a tissue at the cellular level.—Sever, D., Eldor, R., Sadoun, G., Amior, L., Dubois, D., Boitard, C., Aflalo, C., Melloul, D. Evaluation of impaired β‐cell function in nonobese‐diabetic (NOD) mouse model using bioluminescence imaging. FASEB J. 25, 676–684 (2011). www.fasebj.org